Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to 106.85%.

  • Ultragenyx Pharmaceutical's EBITDA Margin fell 122300.0% to 106.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 86.27%, marking a year-over-year increase of 162200.0%. This contributed to the annual value of 95.67% for FY2024, which is 354100.0% up from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's EBITDA Margin stood at 106.85%, which was down 122300.0% from 64.8% recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's EBITDA Margin peaked at 64.8% during Q2 2025, and registered a low of 248.14% during Q3 2022.
  • Moreover, its 5-year median value for EBITDA Margin was 110.02% (2021), whereas its average is 124.3%.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's EBITDA Margin surged by 2251100bps in 2021, and later crashed by -1381200bps in 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's EBITDA Margin (Quarter) stood at 122.99% in 2021, then dropped by -15bps to 140.91% in 2022, then surged by 32bps to 95.81% in 2023, then rose by 23bps to 74.16% in 2024, then tumbled by -44bps to 106.85% in 2025.
  • Its last three reported values are 106.85% in Q3 2025, 64.8% for Q2 2025, and 102.62% during Q1 2025.